In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk's Japan Unit To Apply For Regulatory Approval Of Stronger Insulin Drugs

This article was originally published in PharmAsia News

Executive Summary

The Japanese unit of Danish drug maker Novo Nordisk plans to apply for Japanese approval of a pair of insulin-injection products it hopes to begin marketing next year. Novo Nordisk Pharma already has NovoRapid 30 Mix on the Japanese market, but the two new versions, also rapid-acting, contain higher amounts of insulin aspart. The new variations are NovoRapid 50 Mix and NovoRapid 70 Mix, which Novo Nordisk Pharma hopes will help stave off nascent competition from other drug makers as Japan deals with rising obesity associated with diabetes. (Click here for more - a subscription may be required

You may also be interested in...



Lucky STAR: FDA’s eSTAR Pilot Aims To Make 510(k) Process Smoother With Submission Template For Device Makers

Nine manufacturers will soon have the chance to enroll in a voluntary eSTAR pilot program that the US agency says will make the premarket review process more efficient and consistent. The design and structure of an electronic Submission Template And Resource – or eSTAR – template is similar to templates used by FDA reviewers. An eSTAR won’t change the agency’s statutory or data requirements for sponsors to show substantial equivalence to predicate devices.

E.l.f. Puts Premium On ‘Clean Beauty’ With First Strategic Acquisition: W3ll People

W3ll People is expected to add a relatively modest $7m to e.l.f. Beauty’s fiscal 2021 top line, but the brand has “major white space” opportunities, including at Target, e.l.f.’s longest-standing customer. Further, its plant-based product line includes 40 “EWG Verified” products, reflecting expertise e.l.f. is eager to tap.

UCB Pins Growth Hopes On Burgeoning Late-Stage Pipeline

UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.

 

UsernamePublicRestriction

Register

SC072531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel